Glypican-3 (GPC3), a cell surface glycoprotein, regulates cell growth and exhibits increased expression in hepatocellular carcinoma (HCC) and squamous non-small cell lung cancer (SQ-NSCLC). This study developed an artificial intelligence (AI) algorithm for predicting GPC3 expression to accelerate clinical trial enrollment, comparing it with manual immunohistochemistry (IHC) scoring.
Methods:
Using 167 NSCLC and 133 HCC formalin-fixed paraffin-embedded tumor blocks, GPC3 expression was quantified via IHC assays. Machine learning (ML) models were trained on digitized NSCLC whole slide images to identify GPC3-positive tumor areas, applying data-driven cutoffs for classification. Association between GPC3 and programmed cell death-ligand 1 (PD-L1) IHC expression in NSCLC sample was explored.
Results:
GPC3 expression peaked in HCC (63.9%), followed by SQ-NSCLC (52.6%) and adeno-NSCLC (lung adenocarcinoma) (10.0%). No significant correlation was found between GPC3 and PD-L1 expression in SQ-NSCLC. AI-based screening surpassed clinical pathologists by 10% in precision, achieving 100% recall at a 1% cutoff. ML model quantification aligned well with pathologist consensus. Profiling GPC3 expression emphasized its prevalence in HCC and SQ-NSCLC.
Conclusion:
Our AI platform standardizes, scales, and reproducibly characterizes GPC3 in NSCLC, supporting patient selection in clinical studies.
Get full access to this article
View all access options for this article.
References
1.
GuoM, ZhangH, Zhen GJ, et al.Glypican-3: A new target for diagnosis and treatment of hepatocellular carcinoma. J Cancer, 2020; 11(8):2008–2021; doi: 10.7150/jca.39972
2.
ElgundiZ, PapanicolaouM, MajorG, et al.Cancer metastasis: The role of the extracellular matrix and the heparan sulfate proteoglycan perlecan. Front Oncol, 2019; 9:1482; doi: 10.3389/fonc.2019.01482
3.
HassanN, GreveB, Espinoza-SánchezNA, et al.Cell-surface heparan sulfate proteoglycans as multifunctional integrators of signaling in cancer. Cell Signal, 2021; 77:109822; doi: 10.1016/j.cellsig.2020.109822
4.
LepeddaAJ, NiedduG, PiperigkouZ, KyriakopoulouK, KaramanosN, FormatoM., editors. Circulating heparan sulfate proteoglycans as biomarkers in health and disease. Seminars in Thrombosis and Hemostasis; 2021: Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY… .
5.
YangS, CaiC, WangH, et al.Drug delivery strategy in hepatocellular carcinoma therapy. Cell Commun Signal, 2022; 20(1):26; doi: 10.1186/s12964-021-00796-x
6.
HoM, KimH. Glypican-3: A new target for cancer immunotherapy. Eur J Cancer, 2011; 47(3):333–338; doi: 10.1016/j.ejca.2010.10.024
7.
HsuH-C, ChengW, LaiP-L. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: Biological significance and temporospatial distribution. Cancer Res, 1997; 57(22):5179–5184.
8.
Aviel-RonenS, LauSK, PintilieM, et al.Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol, 2008; 21(7):817–825; doi: 10.1038/modpathol.2008.37
9.
NakatsuraT, KageshitaT, ItoS, et al.Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res, 2004; 10(19):6612–6621; doi: 10.1158/1078-0432.CCR-04-0348
10.
BaumhoerD, TornilloL, StadlmannS, et al.Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol, 2008; 129(6):899–906; doi: 10.1309/HCQWPWD50XHD2DW6
11.
SaikaliZ, SinnettD. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer, 2000; 89(5):418–422.
12.
StadlmannS, GuethU, BaumhoerD, et al.Glypican-3 expression in primary and recurrent ovarian carcinomas. Int J Gynecol Pathol, 2007; 26(3):341–344; doi: 10.1097/pgp.0b013e31802d692c
13.
ZyngerDL, DimovND, LuanC, et al.Glypican 3: A novel marker in testicular germ cell tumors. Am J Surg Pathol, 2006; 30(12):1570–1575; doi: 10.1097/01.pas.0000213322.89670.48
14.
KimH, XuG-L, BorczukAC, et al.The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol, 2003; 29(6):694–701; doi: 10.1165/rcmb.2003-0061OC
15.
MurthySS, ShenT, De RienzoA, et al.Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene, 2000; 19(3):410–416; doi: 10.1038/sj.onc.1203322
16.
XiangY-Y, LadedaV, FilmusJ. Glypican-3 expression is silenced in human breast cancer. Oncogene, 2001; 20(50):7408–7412; doi: 10.1038/sj.onc.1204925
17.
HaruyamaY, KataokaH. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol, 2016; 22(1):275–283; doi: 10.3748/wjg.v22.i1.275
18.
FilmusJ, CapurroM. Glypican‐3: A marker and a therapeutic target in hepatocellular carcinoma. Febs J, 2013; 280(10):2471–2476; doi: 10.1111/febs.12126
19.
CapurroMI, XiangY-Y, LobeC, et al.Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res, 2005; 65(14):6245–6254; doi: 10.1158/0008-5472.CAN-04-4244
20.
ChiaoE, FisherP, CrisponiL, et al.Overgrowth of a mouse model of the Simpson–Golabi–Behmel syndrome is independent of IGF signaling. Dev Biol, 2002; 243(1):185–206; doi: 10.1006/dbio.2001.0554
21.
Paine-SaundersS, VivianoBL, ZupicichJ, et al.glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol, 2000; 225(1):179–187; doi: 10.1006/dbio.2000.9831
22.
SongHH, ShiW, XiangY-Y, et al.The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem, 2005; 280(3):2116–2125; doi: 10.1074/jbc.M410090200
23.
FarooqM, HwangSY, ParkMK, et al.Blocking endogenous glypican-3 expression releases Hep 3B cells from G1 arrest. Mol Cells, 2003; 15(3):356–360.
24.
GonzalezAD, KayaM, ShiW, et al.OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line–specific manner. J Cell Biol, 1998; 141(6):1407–1414; doi: 10.1083/jcb.141.6.1407
25.
LiM, ChooB, WongZ-M, et al.Expression of OCI-5/glypican 3 during intestinal morphogenesis: Regulation by cell shape in intestinal epithelial cells. Exp Cell Res, 1997; 235(1):3–12; doi: 10.1006/excr.1997.3629
26.
SongHH, ShiW, FilmusJ. OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem, 1997; 272(12):7574–7577; doi: 10.1074/jbc.272.12.7574
27.
BaxiV, EdwardsR, MontaltoM, et al.Digital pathology and artificial intelligence in translational medicine and clinical practice. Mod Pathol, 2022; 35(1):23–32; doi: 10.1038/s41379-021-00919-2
28.
PuladiB, OomsM, KintslerS, et al.Automated PD-L1 scoring using artificial intelligence in head and neck squamous cell carcinoma. Cancers (Basel), 2021; 13(17):4409; doi: 10.3390/cancers13174409
29.
WidmaierM, WiestlerT, WalkerJ, et al.Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis. Mod Pathol, 2020; 33(3):380–390; doi: 10.1038/s41379-019-0349-y
30.
KapilA, MeierA, ZurawA, et al.Deep semi supervised generative learning for automated tumor proportion scoring on NSCLC tissue needle biopsies. Sci Rep, 2018; 8(1):17343; doi: 10.1038/s41598-018-35501-5
31.
NguyenH-G, BlankA, DawsonHE, et al.Classification of colorectal tissue images from high throughput tissue microarrays by ensemble deep learning methods. Sci Rep, 2021; 11(1):2371; doi: 10.1038/s41598-021-81352-y
32.
CampanellaG, HannaMG, GeneslawL, et al.Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nat Med, 2019; 25(8):1301–1309; doi: 10.1038/s41591-019-0508-1
33.
KatherJN, Suarez-CarmonaM, CharoentongP, et al.Topography of cancer-associated immune cells in human solid tumors. Elife, 2018; 7:e36967; doi: 10.7554/eLife.36967
34.
LawrieCH, BallabioE, SoilleuxE, et al.Inter‐and intra‐observational variability in immunohistochemistry: A multicentre analysis of diffuse large B‐cell lymphoma staining. Histopathology, 2012; 61(1):18–25; doi: 10.1111/j.1365-2559.2012.04179.x
35.
BeckAH, SangoiAR, LeungS, et al.Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci Transl Med, 2011; 3(108):108ra113; doi: 10.1126/scitranslmed.3002564
36.
YuK-H, ZhangC, BerryGJ, et al.Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features. Nat Commun, 2016; 7(1):12474; doi: 10.1038/ncomms12474
37.
ShamaiG, BinenbaumY, SlossbergR, et al.Artificial intelligence algorithms to assess hormonal status from tissue microarrays in patients with breast cancer. JAMA Netw Open, 2019; 2(7):e197700; doi: 10.1001/jamanetworkopen.2019.7700
38.
ReckM, Rodríguez-AbreuD, RobinsonAG, et al.; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med, 2016; 375(19):1823–1833; doi: 10.1056/NEJMoa1606774
39.
MokTSK, WuY-L, KudabaI, et al.; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet, 2019; 393(10183):1819–1830; doi: 10.1016/S0140-6736(18)32409-7
40.
YamauchiN, WatanabeA, HishinumaM, et al.The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol, 2005; 18(12):1591–1598; doi: 10.1038/modpathol.3800436
41.
JemalA, BrayF, CenterMM, et al.Global cancer statistics. CA Cancer J Clin, 2011; 61(2):69–90; doi: 10.3322/caac.20107
42.
LiJ, RanJ, ChenL-C, et al.Bituminous coal combustion and Xuan Wei Lung cancer: A review of the epidemiology, intervention, carcinogens, and carcinogenesis. Arch Toxicol, 2019; 93(3):573–583; doi: 10.1007/s00204-019-02392-y
43.
ShirakawaH, SuzukiH, ShimomuraM, et al.Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci, 2009; 100(8):1403–1407; doi: 10.1111/j.1349-7006.2009.01206.x
44.
ShamaiG, LivneA, PolóniaA, et al.Deep learning-based image analysis predicts PD-L1 status from H&E-stained histopathology images in breast cancer. Nat Commun, 2022; 13(1):6753; doi: 10.1038/s41467-022-34275-9
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
